Outlook Therapeutics, Inc. is a leading Pharmaceuticals company based in the United States of America. With an ESG score of 33.6, it is considered to be a high-risk investment. Specializing in the development and commercialization of ONS-5010, a monoclonal antibody (mAb) for ophthalmic use, Outlook Therapeutics is dedicated to advancing healthcare solutions.